Abstract

Neutrophils provide first line of host defense against bacterial infections utilizing glycolysis for their effector functions. How glycolysis and its major byproduct lactate are triggered in bone marrow (BM) neutrophils and their contribution to neutrophil mobilization in acute inflammation is not clear. Here we report that bacterial lipopolysaccharides (LPS) or Salmonella Typhimurium triggers lactate release by increasing glycolysis, NADPH-oxidase-mediated reactive oxygen species and HIF-1α levels in BM neutrophils. Increased release of BM lactate preferentially promotes neutrophil mobilization by reducing endothelial VE-Cadherin expression, increasing BM vascular permeability via endothelial lactate-receptor GPR81 signaling. GPR81−/− mice mobilize reduced levels of neutrophils in response to LPS, unless rescued by VE-Cadherin disrupting antibodies. Lactate administration also induces release of the BM neutrophil mobilizers G-CSF, CXCL1 and CXCL2, indicating that this metabolite drives neutrophil mobilization via multiple pathways. Our study reveals a metabolic crosstalk between lactate-producing neutrophils and BM endothelium, which controls neutrophil mobilization under bacterial infection.

Lactate is a by-product of glycolysis that can function via its G protein receptor GPR81. Here the authors show that LPS or Salmonella infection enhances glycolytic metabolism in bone marrow neutrophils, resulting in lactate production, which increases endothelial barrier permeability and mobilization of these neutrophils by targeting endothelial GPR81.

Details

Title
Lactate released by inflammatory bone marrow neutrophils induces their mobilization via endothelial GPR81 signaling
Author
Khatib-Massalha Eman 1 ; Bhattacharya Suditi 1 ; Massalha Hassan 2 ; Biram Adi 1   VIAFID ORCID Logo  ; Golan, Karin 1 ; Kollet Orit 1 ; Kumari Anju 1 ; Avemaria Francesca 1 ; Petrovich-Kopitman Ekaterina 3 ; Gur-Cohen, Shiri 1 ; Itkin Tomer 1 ; Brandenburger Isabell 4 ; Spiegel Asaf 1 ; Shulman Ziv 1   VIAFID ORCID Logo  ; Gerhart-Hines, Zachary 5 ; Shalev, Itzkovitz 2   VIAFID ORCID Logo  ; Gunzer Matthias 6   VIAFID ORCID Logo  ; Offermanns, Stefan 4   VIAFID ORCID Logo  ; Ronen, Alon 1 ; Ariel Amiram 7   VIAFID ORCID Logo  ; Lapidot Tsvee 1   VIAFID ORCID Logo 

 Department of Immunology, Weizmann Institute of Science, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563) 
 Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563) 
 Department of Immunology, Weizmann Institute of Science, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563); Life science Core facilities, Weizmann Institute of Science, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563) 
 Department of Pharmacology, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany (GRID:grid.418032.c) (ISNI:0000 0004 0491 220X) 
 University of Copenhagen, Novo Nordisk Foundation Center for Basic Metabolic Research, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X) 
 University Hospital, University Duisburg-Essen, Institute for Experimental Immunology and Imaging, Essen, Germany (GRID:grid.5718.b) (ISNI:0000 0001 2187 5445) 
 University of Haifa, Department of Human Biology, Haifa, Israel (GRID:grid.18098.38) (ISNI:0000 0004 1937 0562) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2423972153
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.